- BioNTech’s 4Q EPS didn’t meet the estimate, coming in at EU1.90 compared to the predicted EU2.31.
- The revenue for the quarter was EU1.48 billion, lower than the estimated EU1.87 billion.
- Commercial revenue for the quarter was EU1.48 billion, a 65% decline year-on-year, and less than the estimated EU1.62 billion.
- R&D revenue was only EU0.1 million, a 99% decrease year-on-year, significantly lower than the estimated EU7.22 million.
- Research and development expenses were EU577.8 million, a 13% increase year-on-year, but less than the estimated EU689.1 million.
- Operating income was EU526.2 million, an 84% decrease year-on-year, and less than the estimated EU713.1 million.
- BioNTech spent EU83.8 million on purchases of property, plant and equipment, a 39% decrease year-on-year.
- Cash and cash equivalents were EU11.66 billion, a 16% decrease year-on-year, and less than the estimated EU16.85 billion.
- For the year, BioNTech forecasts R&D expenses to be between EU2.40 billion to EU2.60 billion, higher than the estimated EU2.12 billion.
- SG&A expenses are expected to be between EU700 million to EU800 million, higher than the estimated EU624.9 million.
- Capital expenditure is predicted to be between EU400 million to EU500 million.
- BioNTech expects group revenue for the full 2024 financial year to be in the range of €2.5 billion to €3.1 billion.
A look at BioNTech Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to the Smartkarma Smart Scores, BioNTech has a positive long-term outlook. The company has received a score of 4 for value, indicating that it is seen as a valuable investment opportunity. Additionally, BioNTech has a score of 2 for growth, suggesting that it has potential for future growth.
Despite the positive outlook, investors should be aware that BioNTech has a low score of 1 for dividends, meaning it is not likely to provide regular dividend payments. However, the company has a high score of 5 for resilience, indicating that it has a strong ability to withstand market fluctuations and potential challenges.
In terms of momentum, BioNTech has received a score of 3, suggesting that it is currently experiencing positive momentum in the market. Overall, BioNTech is a biotechnology company that offers solutions for cancer treatment and serves customers all around the world.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
